Replimune Group, Inc.

NasdaqGS REPL

Replimune Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.19

Replimune Group, Inc. Debt to Equity Ratio is 0.19 for the Trailing 12 Months (TTM) ending September 30, 2024, a 66.17% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Replimune Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.11, a 43.50% change year over year.
Replimune Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.08, a 16.75% change year over year.
Replimune Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.07, a -63.22% change year over year.
Replimune Group, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.18.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGS: REPL

Replimune Group, Inc.

CEO	Dr. Sushil Patel Ph.D.
IPO Date	July 20, 2018
Location	United States
Headquarters	500 Unicorn Park Drive
Employees	331
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years